PMID- 36015104
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 15
IP  - 8
DP  - 2022 Jul 31
TI  - Efficacy and Safety of Trametinib in Neurofibromatosis Type 1-Associated 
      Plexiform Neurofibroma and Low-Grade Glioma: A Systematic Review and 
      Meta-Analysis.
LID - 10.3390/ph15080956 [doi]
LID - 956
AB  - Trametinib has been used in neurofibromatosis type 1 (NF1) patients, especially 
      those with unresectable nerve tumors, but no systematic review based on the 
      latest studies has been published. We conducted this meta-analysis to evaluate 
      the effectiveness and safety of trametinib in treating NF1-related nerve tumors. 
      Original articles reporting the efficacy and safety of trametinib in NF1 patents 
      were identified in PubMed, EMBASE, and Web of Science up to 1 June 2022. Using R 
      software and the 'meta' package, the objective response rates (ORRs) and disease 
      control rates (DCRs) were calculated to evaluate the efficacy, and the pooled 
      proportion of adverse events (AEs) was calculated. The Grading of 
      Recommendations, Assessment, Development and Evaluation system was used to assess 
      the quality of evidence. Eight studies involving 92 patients were included, which 
      had a very low to moderate quality of evidence. The pooled ORR was 45.3% (95% CI: 
      28.9-62.1%, I(2) = 0%), and the DCR was 99.8% (95% CI: 95.5-100%, I(2) = 0%). The 
      most common AEs was paronychia, with a pooled rate of 60.7% (95% CI: 48.8-72.7%, 
      I(2) = 0%). Our results indicate the satisfactory ability to stabilize tumor 
      progression but a more limited ability to shrink tumors of trametinib in 
      NF1-related nerve tumors. The safety profile of trametinib is satisfactory.
FAU - Wang, Dun
AU  - Wang D
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's 
      Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, 
      China.
AD  - Department of Burn and Plastic Surgery, West China Hospital of Sichuan 
      University, No 37 Wainan Guoxue Road, Chengdu 610041, China.
FAU - Ge, Lingling
AU  - Ge L
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's 
      Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, 
      China.
FAU - Guo, Zizhen
AU  - Guo Z
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's 
      Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, 
      China.
FAU - Li, Yuehua
AU  - Li Y
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's 
      Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, 
      China.
FAU - Zhu, Beiyao
AU  - Zhu B
AUID- ORCID: 0000-0002-6443-5586
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's 
      Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, 
      China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's 
      Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, 
      China.
FAU - Wei, Chengjiang
AU  - Wei C
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's 
      Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, 
      China.
FAU - Li, Qingfeng
AU  - Li Q
AUID- ORCID: 0000-0001-7822-618X
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's 
      Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, 
      China.
FAU - Wang, Zhichao
AU  - Wang Z
AUID- ORCID: 0000-0002-5859-4193
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's 
      Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, 
      China.
LA  - eng
GR  - 82102344; 82172228/National Natural Science Foundation of China/
GR  - 20QA1405600/Shanghai Rising Star Program supported by Science and Technology 
      Commission of Shanghai Municipality/
GR  - 19JC1413/Science and Technology Commission of Shanghai Municipality/
GR  - 22ZR1422300/Natural Science Foundation of Shanghai/
GR  - 19CG18/"Chenguang Program" supported by Shanghai Education Development Foundation 
      (SHEDF)/
GR  - shslczdzk00901/Shanghai Municipal Key Clinical Specialty/
GR  - SSMU-ZDCX20180700/Innovative research team of high-level local universities in 
      Shanghai/
PT  - Journal Article
PT  - Review
DEP - 20220731
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC9415905
OTO - NOTNLM
OT  - low-grade Glioma
OT  - meta-analysis
OT  - neurofibromatosis type 1
OT  - plexiform neurofibroma
OT  - systematic review
OT  - trametinib
COIS- There is no conflict of interests for all authors.
EDAT- 2022/08/27 06:00
MHDA- 2022/08/27 06:01
PMCR- 2022/07/31
CRDT- 2022/08/26 01:41
PHST- 2022/06/30 00:00 [received]
PHST- 2022/07/27 00:00 [revised]
PHST- 2022/07/27 00:00 [accepted]
PHST- 2022/08/26 01:41 [entrez]
PHST- 2022/08/27 06:00 [pubmed]
PHST- 2022/08/27 06:01 [medline]
PHST- 2022/07/31 00:00 [pmc-release]
AID - ph15080956 [pii]
AID - pharmaceuticals-15-00956 [pii]
AID - 10.3390/ph15080956 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2022 Jul 31;15(8):956. doi: 10.3390/ph15080956.